New drug aims to supercharge CAR T-Cells against tough lymphoma
NCT ID NCT07052305
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatment to see if it is safe and tolerable. The goal is to improve tumor response and outcomes for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NT-I7 (Efineptakin alfa)
What this could lead to
If it works, this could improve how well CAR T-cells fight lymphoma and lead to better long-term outcomes for patients.
What could go wrong
This is a very early phase 1 trial with only 24 participants, so safety and effectiveness are not yet proven. There may be side effects or no benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact